SG+I
Phase 2Small molecule
SG+I is one of 54 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
96 competitors in Triple-Negative Breast Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Trodelvy
GileadPhase 3
Tecentriq
RochePhase 3
Halaven
EisaiPhase 3
Paraplatin
AAvyxa
Phase 3
Gemzar
Johnson & JohnsonPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Imfinzi
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SG+I. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details